GlassScriptPhysician profile
Daniel Groisser
NPI 1376514745
$70,593.46
in general payments reported to CMS, 2019-2025
46 companies · $25K in 2025
The $25K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,495 · 2020: $16K · 2021: $4,064 · 2022: $3,190 · 2023: $6,653 · 2024: $14K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,820 · Travel and Lodging: $2,885 · Honoraria: $2,750 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,823.75 |
| Food and Beverage | $12,465.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,820.00 |
| Travel and Lodging | $2,884.66 |
| Honoraria | $2,750.00 |
| Education | $310.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $10,725.17 | 2019-2025 | |
| Pfizer INC. | $8,849.62 | 2019-2025 | |
| Abbvie INC. | $6,808.73 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $6,481.71 | 2021-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $6,255.99 | 2020-2025 | Ilumya, Blu-U, Odomzo |
| Novartis Pharmaceuticals Corporation | $5,563.83 | 2020-2025 | |
| Eli Lilly and Company | $5,414.04 | 2025 | Ebglyss |
| Janssen Biotech, INC. | $3,696.52 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Lnhc, INC | $2,884.26 | 2025 | Zelsuvmi |
| Genzyme Corporation | $2,051.17 | 2020-2025 | |
| Ucb, INC. | $1,698.09 | 2019-2025 | Bimzelx, Cimzia |
| Epi Health, LLC | $1,697.71 | 2020-2022 | |
| Incyte Corporation | $1,097.74 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $1,078.63 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Medimetriks Pharmaceuticals, INC. | $1,050.00 | 2022-2024 | Neo-Synalar, Tovet (Emollient Formulation) |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Groisser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.